NASDAQ: AVBPArrivent Biopharma Inc Stock
$15.44-0.10 (-0.64%)
Updated Apr 26, 2024
AVBP Price
$15.44
Fair Value Price
N/A
Market Cap
$471.97M
52 Week Low
$14.35
52 Week High
$25.95
P/E
-0.48x
P/B
-3.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$69.33M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.08
Operating Cash Flow
-$56M
Beta
0.49
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVBP Overview
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVBP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AVBP is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AVBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AVBP due diligence checks available for Premium users.
Be the first to know about important AVBP news, forecast changes, insider trades & much more!
AVBP News
Valuation
AVBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.48x
Industry
14.88x
Market
41.14x
AVBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.08x
Industry
5.85x
AVBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.2M
Profit Margin
0%
AVBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$163.1M
Liabilities
$11.8M
Debt to equity
-0.08
AVBP's short-term assets ($159.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVBP's short-term assets ($159.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.9M
Investing
$25.0M
Financing
-$1.1M
AVBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVBP vs Biotech Stocks
Arrivent Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.